The U.S. Securities and Exchange Commission (SEC) is now at trial in an enforcement action against former biopharmaceutical executive Matthew Panuwat, related to so-called "shadow trading" activities. Panuwat allegedly purchased call options in biopharmaceutical company Incyte a mere seven minutes after learning that his own employer, Medivation, expected to be acquired by Pfizer. When Medivation announced its acquisition, Incyte's stock price jumped approximately 8%, netting Panuwat about $107,000 in profit.